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Abstract 
Background: Previous reports have revealed that down-regulation of miR-34a expression can promote colorectal 
cancer (CRC) cell growth by targeting cell cycle-related transcriptional factor E2F1. To date, the function of the single 
nucleotide polymorphism (SNP) located in the mature region of miR-34a has not been investigated.
Methods: We performed a case–control study including 685 CRC patients and 618 cancer-free controls. Genotyp-
ing, real-time PCR assay, cell transfection, and the dual luciferase reporter assay were used in our study. Cell prolifera-
tion and cell cycle analysis were measured in CRC cells including Hct-116 and SW480. The overall survival of different 
genotypes was also investigated.
Results: We found that the rs35301225 polymorphism in miR-34a was involved in the occurrence of CRC by acting 
as a tumor suppressor by down-regulation of tumor-promoting gene E2F1. C/A SNP of miR-34a could promote CRC 
cell proliferation by up-regulation of E2F1. Also, C/A genotype can change the cell cycle by increasing the S phase 
percentage. Moreover, the SNP in rs35301225 of miR-34a was associated with tumor size and tumor differentiation, as 
well as metastasis in CRC patients; C/A SNP was related to the significantly enhanced expression of E2F1 and shorter 
survival in post-surgery CRC patients.
Conclusions: rs35301225 in miR-34a was highly associated with a decreased risk of CRC in a Chinese population and 
might serve as a novel biomarker for colon cancer.
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Background
Colorectal cancer (CRC) is cancer in the colon or rec-
tum. Risk factors for CRC include lifestyle, older age, and 
inherited genetic disorders [4, 5]. CRC recurrence rates 
are high among all populations, and surgery and combi-
nation chemotherapies have been shown to confer only 
modest survival benefits in advanced CRC, resulting in 
an overall 5-year survival rate of 24% [1]. Therefore, the 
development of new strategies for its primary prevention, 
early diagnosis, metastasis inhibition, and treatments are 
urgently needed.
miRNAs are a class of small non-coding RNA molecules 
that regulate gene expression by binding to partially com-
plementary recognition sequences of target mRNAs [2, 3]. 
miRNAs have important roles in various biological and 
pathological processes, such as development, cell prolif-
eration, differentiation, apoptosis, inflammation, stress 
response and migration [4–6]. Single nucleotide polymor-
phism (SNP) of miRNA was a novel mechanistic explana-
tion for different targeting gene expression, the variant in 
miRNA especially in the mature form of miRNA could 
switch the binding force of target site and thus to cause 
increased transcription of targeting genes [7, 8].
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Early in 2011, Zauli et  al. reported that miR-34a was 
down-regulated in human leukemia which was essential 
in the development of leukemia by targeting two onco-
genic factors: E2F1 and B-myc [9]. E2F1 expression was 
affected in colon cancer patients [10–12]. However, there 
is no report concerning SNP of miR-34a. Therefore, in 
this study, we sought to assess the association between 
a candidate SNP in miR-34a and susceptibility to colon 
cancer and its precursor in a Chinese population group. 
We also investigated whether the risk-associated poly-
morphism contributes toward colon cancer patients out-
come, and the detailed mechanism involved.
Methods
Clinical sample information
The Hospital-based case–control study consists of 685 
patients newly diagnosed with CRC and 618 cancer-free 
controls. All the subjects were recruited from the Jiangyin 
Hospital of Chinese Traditional Medicine, Anting Hospital 
and Central Hospital of Jiading district between February 
2009 and August 2015. Patients with other hematological 
disorders, previous history of cancers, radiotherapy and 
chemotherapy were excluded. The cancer-free control sub-
jects from the same geographic area showed no evidence 
of a genetic relationship with the cases. The patients were 
classified according to World Health Organization clas-
sification. This study was approved by the Institutional 
Review Board of Jiangyin Hospital of Chinese Traditional 
Medicine, and every patient had written informed con-
sent. The clinical features of all the cases and controls were 
presented in Table 1.
Cell lines and cell culture
Colon cancer cell lines including Hct-116 and Sw-480 
were purchased from American Type Culture Collec-
tion. All cells were cultured in Dulbecco modified Eagle 
medium (DMEM) purchased from Gibco (CA, USA) 
supplemented with 10% fetal bovine serum (Invitrogen, 
Carlsbad, USA) and grown in humidified 5% CO2 at 
37 °C.
Construction of plasmids
The total fragment of the E2F1 3′UTR and its pGL3 Lucif-
erase Reporter Vectors mutated form were amplified. 
The PCR products were cloned into the pGL3 Luciferase 
Reporter Vectors (Promega, CA, USA). The construction 
containing both CC and AA type of miR-34a were also 
synthesized and cloned into pSilence 2.1-U6.
Dual‑luciferase reporter assay
The treated cells harvested 48  h after miRNA treat-
ment, and the firefly luciferase expression was measured 
and normalized to Renilla activities. Dual-luciferase 
assays (Promega, Madison, WI) were performed accord-
ing to the manufacturer’s protocol and detected with a 
Fluoroskan microplate reader (Thermo Labsystems, Hel-
sinki, Finland). Transfection was repeated three times in 
triplicate.
Cell proliferation assays
Cell proliferation was monitored using CCK-8 (Dojin 
Laboratories, Kumamoto, Japan) according to the manu-
facturer’s instructions. In short, the mock and infected 
cells were seeded at a density of 1  ×  104 cells/well in 
96-well flat-bottom plates. CCK-8 was added to each well 
containing 100 μL of the culture medium, and the plate 
was incubated for 3 h at 37 °C. Viable cells were evaluated 
by measuring the absorbance at 450 nm, using a micro-
plate reader.
Immunohistochemistry (IHC)
Sections were stained according to the previous publi-
cation [11]. The section was incubated with in primary 
mouse anti-human Ab for E2F1(Ab112580), the sections 
were stained with DAB according to manufacturer’s pro-
tocols and mounted and photographed using a digital-
ized microscope camera (Nikon, Tokyo, Japan).
Genotype
Genomic DNA was extracted from peripheral blood by 
using QIAamp DNA blood mini kits (Qiagen, Hilden, 
Table 1 Clinical characteristic of  colon cancer patients 
and cancer-free controls
* Two-sided Chi square test for either genotype distributions or allele 
frequencies between cases and controls
Variables Cases (n = 685) Controls (n = 618) P*
N % N %
Age (years)
 ≤50 376 54.89 345 55.83 0.738
 >50 309 45.11 273 44.17
Gender
 Male 318 46.42 319 51.62 0.067
 Female 367 53.58 299 48.38
Tumor size (cm)
 ≤5 478 69.78
 >5 207 30.22
Differentiation
 Well 249 36.35
 Moderate 205 29.93
 Poor 231 33.72
Metastasis
 Yes 412 60.15
 No 273 39.85
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Germany) according to the manufacturer’s instructions. 
Genotyping was performed with the TaqMan SNP Gen-
otyping Assay. The PCR reactions were carried out in a 
total volume of 5 μL containing TaqMan Universal Mas-
ter Mix, SNP Genotyping AssayMix, DNase-free water 
and genomic DNA. The PCR conditions were 2  min at 
50 °C, 10 min at 95 °C, followed by 40 cycles at 95 °C for 
15 s and 60 °C for 1 min. The 384-well ABI 7900HT Real-
Time PCR System was applied (ABI, CA, USA).
Statistical analysis
All experiments were performed in triplicate and 
repeated at least three times. Data were expressed as 
mean ± SD. The association between rs35301225 geno-
types and the risk of CRC was evaluated by calculating 
the odds ratios (ORs) and their 95% confidence intervals 
(CIs) using univariate and multivariate logistic regression 
analysis. Differences between two independent groups 
were tested with Student’s t test. All statistical analyses 
were carried out using SPSS version 18.0 and presented 
with Graphpad Prism software. Kaplan–Meier survival 
curves were plotted, and the log-rank test was done. The 
significance of various variables for survival was analyzed 
by the Cox proportional hazards model in a multivariate 
analysis. The results were considered to be statistically 
significant at P < 0.05.
Results
Clinical significance of rs35301225 in CRC
We first detected genotype frequencies in 685 CRC cases 
and 618 healthy controls, whose characteristics are listed 
in Table  1. As shown in Table  2, Chi square statistical 
analysis revealed that the genotypes of rs35301225 fol-
lowed a Hardy–Weinberg equilibrium distribution pat-
tern in the healthy control group (P  =  0.51) (data not 
shown). Further statistical analysis demonstrated that 
the CA genotype and AA genotype presented a signifi-
cantly increased risk of CRC (P < 0.0001; for CA: Odds 
ratio (OR)  =  1.15, P  <  0.0001 and for AA: OR  =  3.71, 
P  <  0.0001). Furthermore, the A carrier group also 
carried an increased risk of CRC (OR = 2.08, P < 0.0001). 
All ORs were adjusted for sex, age, smoking status, drink-
ing history, and family cancer history.
Stratified analysis of correlation between miR‑34a 
polymorphism and CRC
Next, we conducted a stratified analysis to understand the 
correlation between the SNP rs35301225 genotypes and 
the clinical characteristics of CRC (Table 3). We found a 
significant association of the rs35301225 genotypes with 
the tumor size, poor differentiation, and metastasis. A 
carrier was related to larger tumor and poor differentia-
tion (P < 0.0001).
The effect of rs35301225 on the regulatory role of miR‑34a 
on E2F1 expression
Since the SNP rs35301225 was predicted to be located in 
the binding site of miR-34a on 3′UTR of E2F1, and the 
previous study revealed that the expression of E2F1 was 
regulated by miR-34a [9], we proposed that SNP of miR-
34a might affect the regulation of E2F1 by miR-34a. We 
investigated the possible SNPs of miR-34a, and deter-
mined that there is an SNP in the mature form of miR-34, 
possibly affecting its binding on 3′UTR of E2F1 (Fig. 1a). 
To test whether or not the inhibitory effect of miR-34a 
was impacted by this SNP, we first measured cell prolif-
eration by treated cells with miR-34a harboring different 
genotypes, including CC and AA. We found that cell pro-
liferation could be suppressed by transfection of miR-34a 
including AA and CC compared to wild type control, but 
the proliferation of CRC cells transfected by miR-34a AA 
was significantly faster than miR-34a CC (Fig.  1b). Next, 
the cell cycle was analyzed: miR-34a AA can significantly 
increase the percentage of S phase of both Hct-116 and 
sw-480 cells compared to the CC genotype (Fig. 1c). Fur-
thermore, the expression of E2F1 was analyzed by western-
blot which indicated that E2F1 expression was significantly 
decreased in the CC group compared to AA (Fig.  1d). 
Next, we constructed pGL3 vectors containing the 3′UTR 
region of E2F1 and then co-transfected it with miR-34a 
Table 2 Genotype frequencies of the miR-34a rs35301225 in colon cancer patients and cancer-free controls
Italic values indicate statistically significant associations
a The ORs, 95% CIs and P value were calculated after adjusting for age, gender
Genotype Cases (n = 685) Controls (n = 618) OR (95%CI)a P valuea
N % N %
rs35301225
 CC 189 27.59 328 53.07 1 <0.0001
 CA 155 22.63 184 29.77 1.15 (1.02–1.11)
 AA 341 49.78 106 17.15 3.71 (1.12–1.21)
 A carrier 496 72.41 290 46.93 2.08 (1.19–1.29) <0.0001
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Table 3 Stratified analysis of rs35301225 genotype in clinical characteristic of gastric cancer patients
* Two-sided Chi square test for either genotype distributions or allele frequencies between cases and controls
Feather Genotype CC vs. AA
P value*
CC vs. A carrier
P value*
CC CA AA A carrier
Age (years)
 ≤50 99 81 196 277 0.258 0.4399
 >50 90 74 145 219
Gender
 Male 80 69 169 238 0.11 0.1990
 Female 109 86 172 258
Differentiation grade
 Well 102 75 72 147 <0.0001 <0.0001
 Moderate 48 69 74 143
 Poor 39 11 195 206
Tumor size (cm)
 ≤5 157 144 177 321 <0.0001 <0.0001
 >5 32 11 164 175
Metastasis
 Yes 147 134 131 265 <0.0001
 No 42 21 210 231 <0.0001
Fig. 1 rs35301225 in miR-34a on the regulatory on E2F1 expression and cell proliferation. a Cell proliferation was measured by CCK8 assay in Hct-
116 and sw-480 cell lines. Cells were treated with miR-34a harboring CC or AA genotype and control by vector transfection. b S phase of Hct-116 
and sw-480 treated with miR-34a harboring CC or AA genotype was determined by flow cytometry. c Expression of E2F1 in of Hct-116 and sw-480 
treated with miR-34a harboring CC or AA genotype were determined by western-blot. d Cells were co-transfected with miR-34a with CC or AA 
genotype, Renilla luciferase vector pGL3-Luc for 48 h. Both firefly and Renilla luciferase activities were measured in the same sample. Firefly lucif-
erase signals were normalized with Renilla luciferase signals. Data was presented as the mean ± SEM. *P < 0.05 and **P < 0.01
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with different genotypes in CRC cell lines. As shown in 
Fig. 1e, we found that the over-expression of miR-34a with 
the AA genotype could attenuate the suppression caused 
by miR-34a with CC in both colon cancer cell lines.
C/A SNP was associated with high expression of E2F1 
and shorter post‑operative survival in clinical CRC patients
We also measured the expression of E2F1 in clinical 
samples with different genotypes of rs35301225. E2F1 
expression was detected in human colon cancer by IHC. 
The staining was divided into high, medium, and low 
component categories. The CC group components were 
significantly different to the A carrier (CA/AA) groups 
in E2F1 expression (high 8.1%, medium 42.8%, and low 
49.1% for the CC group; high 61.6%, medium 24.3%, and 
low 14.1% for the CA/AA groups, P < 0.001) (Fig. 2a, b). 
Real-time PCR further confirmed differences in E2F1 
transcription, but there was no significant difference in 
Fig. 2 rs35301225 in miR-34a on the expression of E2F1 in clinical samples and overall survival of CC patients. a Representative figures for IHC stain-
ing of E2F1 in CC tumor section. b Comparison of components of IHC staining in both in CC and CA/AA genotype CC patients. c, d The expression 
level of E2F1 and miR-34a were determined by real-time PCR in CC and CA/AA genotype CC patients. e overall survival rate of post-surgery CC 
patients were analyzed by Kaplan–Meier survival curves. Data was presented as the mean ± SEM. *P < 0.05 and **P < 0.01
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miR-34a expression between these two groups (Fig.  2c, 
d). All of the results above might indicate that the A gen-
otype in miR-34a might serve as a protective factor in 
CRC by affecting the binding of miR-34a on E2F1.
Among the total 685 CRC patients, we have 206 
patients with follow-up survival data, and these can be 
further divided into CC (n = 89) and CA/AA (n = 117). 
We assessed the 5-year survival rate in the four groups. 
The 5-year survival rate in the CC group was 36.2%, 
which was significantly higher than in the CA/AA group 
with a survival rate of only 9.35% (95% CI: HR = 1.977, 
P = 0.008) (Fig. 2e).
Discussion
Emerging data have shown that the aberrant expression 
of miRNAs contributes to tumorigenesis by inhibiting 
the expression of their target genes and that they poten-
tially serve as biomarkers for prediction and prognosis 
in various cancers, including cervical cancer [13–15]. It 
has been identified that the SNP located in miRNA might 
also cause an abnormal function of the miRNA in regu-
lating the potential target genes. For example, researchers 
have found that a genetic variant in miR-27a contributes 
to colon cancer susceptibility through affecting miR-
27a and target gene expression [16]. SNPs occurring in 
miRNA sequences can affect processing and binding 
ability of mature miRNAs. Functional SNPs of miRNA-
146a [19] have been found associated with cancer sus-
ceptibility, including lung cancer. Our results comprise 
new supplementary data for a function of a miRNA SNP 
contributing to colon cancer development. We found 
that the SNP of miR-34a has a C/A shift which can lead 
to dysregulation of the target gene E2F1, and cause rel-
atively high expression of E2F1. Moreover, this SNP is 
clinically associated with bigger tumor size, lower differ-
entiation, and tumor metastasis.
miR-34a is a tumor-suppressive miRNA which was 
reported to be capable of suppressing proliferation of a 
colon cell line by targeting E2F1 [17]. And with the accu-
mulating of research data concerning miR-34a, more 
target of miR-34a were verified, Akao et al. reported that 
miR-34a was related to chemotherapy-resistant via sup-
pressing of Sirt 1 and E2F3 also in human colon cancer 
[18]. Also, more and more study indicated miR-34a as a 
valuable index in colon cancer diagnosis. Recently, one 
of the group reported that circulating miR-34a capable 
of distinguishing patient groups with different diseases 
of the colon, and moreover, patients with advanced can-
cer from benign disease groups [19]. In present study, we 
also confirmed the regulation effect of miR-34a on E2F1 
in human colon cancer, and furthermore, we find its reg-
ulation effect can be affected by SNP, CA/AA genotype of 
miR-34a was associated with stronger expression of E2F1 
and relatively shorter post-operation survival, this result 
could be another explanation of variation expression of 
E2F1 within human colon cancer.
Conclusions
We report the first evidence that the SNP rs35301225 
located in miR-34a might be a protective factor to pre-
vent the binding on 3′UTR of E2F1, which might sup-
press tumor growth in human CRC.
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